StevanatoSTVN
STVN
About: Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Employees: 5,521
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
9% more capital invested
Capital invested by funds: $1.08B [Q3] → $1.19B (+$103M) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 44
0.5% more ownership
Funds ownership: 109.54% [Q3] → 110.05% (+0.5%) [Q4]
0% more funds holding
Funds holding: 129 [Q3] → 129 (+0) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
71% less call options, than puts
Call options by funds: $15K | Put options by funds: $52K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$24
2%
downside
Avg. target
$24
2%
downside
High target
$24
2%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
UBS John Sourbeer 67% 1-year accuracy 2 / 3 met price target | 2%downside $24 | Neutral Maintained | 7 Mar 2025 |
Financial journalist opinion
Based on 6 articles about STVN published over the past 30 days
Neutral
Seeking Alpha
6 days ago
Stevanato Group S.p.A. (STVN) Q1 2025 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Lisa Miles - SVP & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Paul Knight - KeyBanc Michael Ryskin - Bank of America David Windley - Jefferies Tejas Savant - Morgan Stanley Steven McLaurin Etoch - Stephens Inc Patrick Donnelly - Citi Doug Schenkel - Wolfe Research Operator Good afternoon.
Neutral
Business Wire
1 week ago
Stevanato Group to Participate in Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences. Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of America Securities Healthcare Conference in Las Vegas Wednesday, June 4, 2025, at 1:20 p.m. (CT) – Presentat.
Positive
Zacks Investment Research
1 week ago
Stevanato Group (STVN) Q1 Earnings and Revenues Top Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.09 per share a year ago.
Neutral
Business Wire
1 week ago
Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. First Quarter 2025 Highlights (comparisons to prior-year period) Revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue. Gross.
Positive
Zacks Investment Research
1 week ago
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
Neutral
Business Wire
3 weeks ago
Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2025 on Thursday, May 8, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 8, 2025, to discuss fina.
Neutral
Business Wire
2 months ago
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Healthcare Forum taking place from Tuesday, March 18 to Wednesday, March 19, 2025. The Company will present on Tuesday, March 18, at 3.00 p.m. (ET). A live webcast will be available on the Company.
Negative
Seeking Alpha
2 months ago
Stevanato: Ramping Syringe Demand, Buy Confirmed
Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides downside protection in case of tariff war.
Neutral
Seeking Alpha
2 months ago
Stevanato Group S.p.A. (STVN) Q4 2024 Earnings Call Transcript
Stevanato Group S.p.A. (NYSE:STVN ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Lisa Miles - SVP, IR Franco Stevanato - Chairman and CEO Marco Dal Lago - CFO Conference Call Participants Michael Ryskin - Bank of America Matt Larew - William Blair Patrick Donnelly - Citi David Windley - Jefferies Pete Lukas - CJS Securities Anna Snopkowski - KeyBanc Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Operator Good afternoon.
Positive
Zacks Investment Research
2 months ago
Stevanato Group (STVN) Meets Q4 Earnings Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.20 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.19 per share a year ago.
Charts implemented using Lightweight Charts™